We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $20B
1-Year Est. Return 154.41%
This Fund
S&P 500
This Quarter Est. Return
+1.74%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$7.1B
AUM Growth
+$59.7M
Cap. Flow
-$1.53B
Cap. Flow %
-21.52%
Top 10 Hldgs %
75.68%
Holding
101
New
15
Increased
16
Reduced
17
Closed
6

Top Buys

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$78.6M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$57.7M
3
ANAC
ANACOR PHARMACEUTICALS INC COM
ANAC
+$22.5M
4
DYAX
DYAX CORPORATION
DYAX
+$15.4M
5
QCOR
QUESTCOR PHARMA INC
QCOR
+$13.6M

Top Sells

Rank Stock Value
1
VPHM
VIROPHARMA INC
VPHM
+$220M
2
GILD icon
Gilead Sciences
GILD
+$48M
3
PCYC
PHARMACYCLICS INC
PCYC
+$35.3M
4
ARIA
Ariad Pharmaceuticals Inc
ARIA
+$24.5M
5
AEGR
Aegerion Pharmaceuticals
AEGR
+$24.5M

Sector Composition

Rank Sector Weight
1 Healthcare 50.41%
2 Miscellaneous 49.59%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AVNR
26
DELISTED
AVANIR PHARMACEUTICALS, INC CL A
AVNR
$18.2M 0.26%
5,428,591
+1,000,000
+23% +$4.13M
DYAX
27
DELISTED
DYAX CORPORATION
DYAX
$15.3M 0.22%
+2,026,537
New +$15.4M
ACGN
28
DELISTED
Aceragen Inc
ACGN
$14.7M 0.21%
2,918
-2,478
-46% -$6.61M
SGYP
29
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
$14.7M 0.21%
2,644,787
– –
INSM icon
30
Insmed
INSM
$27.4B
$13.5M 0.19%
796,378
-149,425
-16% -$2.29M
STML
31
DELISTED
Stemline Therapeutics, Inc.
STML
$13.2M 0.19%
675,042
-125,358
-16% -$3.35M
KYTH
32
DELISTED
KYTHERA BIOPHARMACEUTICALS, INC COM
KYTH
$11.7M 0.16%
313,191
+48,191
+18% +$2M
IONS icon
33
Ionis Pharmaceuticals
IONS
$8.55B
$9.84M 0.14%
247,036
– –
ZGNX
34
DELISTED
Zogenix, Inc.
ZGNX
$9.46M 0.13%
343,875
+93,750
+37% +$2.1M
PRTA icon
35
Prothena Corp
PRTA
$458M
$8.94M 0.13%
336,918
-32,732
-9% -$821K
MTEM
36
DELISTED
Molecular Templates, Inc.
MTEM
$8.65M 0.12%
11,227
– –
TGTX icon
37
TG Therapeutics
TGTX
$8.27B
$8.58M 0.12%
2,199,656
+1,599,656
+267% +$6.46M
QLTI
38
DELISTED
QLT Inc
QLTI
$8.55M 0.12%
1,535,863
– –
WINT
39
DELISTED
Windtree Therapeutics Inc
WINT
$8.37M 0.12%
265,616
+157,143
+145% +$4.91M
ARRY
40
DELISTED
Array Biopharma Inc
ARRY
$7.51M 0.11%
1,500,000
– –
AMBI
41
DELISTED
Ambit Biosciences Corp
AMBI
$7.21M 0.1%
747,954
-8
-0% -$107
OMER icon
42
Omeros
OMER
$1.26B
$6.87M 0.1%
608,404
– –
NVAX icon
43
Novavax
NVAX
$1.58B
$6.59M 0.09%
64,346
-21,500
-25% -$1.52M
IRWD icon
44
Ironwood Pharmaceuticals
IRWD
$689M
$6.34M 0.09%
652,115
+101,490
+18% +$911K
OSIR
45
DELISTED
Osiris Therapeutics, Inc. Common Stock
OSIR
$6.04M 0.09%
375,282
– –
XNPT
46
DELISTED
XENOPORT, INC.
XNPT
$5.95M 0.08%
1,034,112
– –
SGMO
47
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$5.89M 0.08%
424,308
+247,601
+140% +$2.85M
PTLA
48
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$5.78M 0.08%
224,434
-75,477
-25% -$1.83M
AERI
49
DELISTED
Aerie Pharmaceuticals
AERI
$5.39M 0.08%
+300,000
New +$3.91M
XNCR icon
50
Xencor
XNCR
$1.81B
$5.03M 0.07%
+550,000
New +$4.72M
1
2
3 4

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Baker Bros. Advisors's Q4 2013 Portfolio in Review

As of Q4 2013, Baker Bros. Advisors held 101 positions worth $7.1B, up 0.85% from $7.04B the previous quarter. Its ten largest holdings account for 76% of the portfolio.

Baker Bros. Advisors withdrew a net $1.53B in Q4 2013, closing 6 positions and reducing 17 holdings. Its most notable exit was VIROPHARMA INC, an estimated $220M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 50% of assets, up from 48% a quarter earlier, followed by Miscellaneous.

Against the trend, Baker Bros. Advisors opened a new position in DYAX CORPORATION worth $15.3M.

  • Baker Bros. Advisors's largest Q4 2013 buy was DYAX CORPORATION: 2,026,537 shares worth $15.3M.
  • Baker Bros. Advisors added most to BioMarin Pharmaceuticals in Q4 2013, an estimated $78.6M increase.
  • Baker Bros. Advisors's biggest Q4 2013 reduction was Gilead Sciences, cutting an estimated $48M.
  • Baker Bros. Advisors fully exited VIROPHARMA INC in Q4 2013, selling an estimated $220M.
  • Baker Bros. Advisors's ten largest holdings make up 76% of its $7.1B portfolio in Q4 2013.
  • Baker Bros. Advisors opened 15 new positions and closed 6 in Q4 2013.
  • Baker Bros. Advisors's portfolio value rose 0.85% quarter-over-quarter to $7.1B.

Based on Baker Bros. Advisors's 13F filing for Q4 2013, filed 14 Feb 2014.